Highlights

  • Alterity Therapeutics Ltd (ASX: ATH) traded at $0.53 as at 3:00pm AEST on August 7, 2026.
  • The stock recorded an increase of approximately 0.95 percent for the session based on the data reviewed.
  • Shares traded within an intraday range of $0.51 to $0.535.
  • Market capitalisation stood at approximately $115.42 million.
  • Trading volume reached 45,073 shares during the session.

Alterity Therapeutics Ltd (ASX: ATH) shares were trading at $0.53 as at 3:00pm AEST on August 7, 2026, after recording an increase of approximately 0.95 percent during the session. The stock traded within an intraday range of $0.51 to $0.535, while the broader S&P/ASX 200 Health Care Index moved lower during the same period.

Alterity Therapeutics Share Price Movement on August 7, 2026

The data reviewed showed that Alterity Therapeutics shares recorded an increase of approximately 0.95 percent for the session. The stock traded between an intraday low of $0.51 and a high of $0.535.

The daily movement represented activity within a narrow trading range. Share price movements for biotechnology companies can vary depending on company-specific developments, market participation, sector sentiment and broader conditions affecting health care stocks.

Trading Volume and Market Capitalisation

Trading volume for Alterity Therapeutics reached 45,073 shares during the session. Based on the reported share price, the company’s market capitalisation stood at approximately $115.42 million.

The trading volume reflected market participation during the reviewed period, while the company’s market capitalisation placed it among the smaller-capitalisation biotechnology companies within the ASX health care sector.

One-Year Share Price Performance

Over the trailing one-year period, Alterity Therapeutics recorded a decline of approximately 18.46 percent based on the data reviewed.

Clinical-stage biotechnology companies can experience changes in share price over time due to company-specific developments, research progress, regulatory updates and broader investor sentiment toward the biotechnology sector.

ASX Health Care Sector Performance

The broader S&P/ASX 200 Health Care Index (XHJ) was trading at 28,010.8 points, down 224.7 points or 0.80 percent, as at 3:20pm AEST on August 7, 2026, with the market session still open.

The index traded within an intraday range of 27,808.8 to 28,235.5 points against a previous close of 28,235.5. Over the past 52 weeks, the index ranged between 21,947.2 and 45,579.6 points, with a one-year return of negative 37.37 percent.

Individual health care stocks can record movements that differ from the broader index due to company-specific factors, trading activity and changes in investor participation.

About Alterity Therapeutics Ltd

Alterity Therapeutics Ltd is an Australian clinical-stage biotechnology company listed on the ASX under the ticker code ATH and classified within the health care sector.

Companies operating within biotechnology can experience share price activity influenced by research and development updates, sector sentiment and broader market conditions.

Understanding the Trading Data

The share price, trading volume and market capitalisation figures provide an overview of Alterity Therapeutics’ market activity during the reviewed session.

Trading volume represents the number of shares exchanged during the period, while market capitalisation reflects the market value based on the reported share price and shares on issue. A single trading session represents short-term market activity and does not necessarily indicate a longer-term trend.

Conclusion

As at 3:00pm AEST on August 7, 2026, Alterity Therapeutics Ltd (ASX: ATH) shares were trading at $0.53, within a day range of $0.51 to $0.535, on trading volume of 45,073 shares and a market capitalisation of approximately $115.42 million.

The stock recorded an increase of approximately 0.95 percent during the session, while the broader S&P/ASX 200 Health Care Index traded lower. Over the trailing one-year period, Alterity Therapeutics recorded a decline of approximately 18.46 percent based on the data reviewed.